尿 S-腺苷甲硫氨酸与慢性肾脏病患者肾功能不全程度相关。
Urine S-Adenosylmethionine are Related to Degree of Renal Insufficiency in Patients with Chronic Kidney Disease.
机构信息
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Department of Molecular and Cell Pathophysiology, Institute of General Pathology and Pathophysiology, Moscow, Russia.
出版信息
Lab Med. 2021 Jan 4;52(1):47-56. doi: 10.1093/labmed/lmaa034.
OBJECTIVE
To determine whether urine S-adenosylmethionine (SAM) might be an indicator of chronic kidney disease (CKD).
METHODS
We investigated urine levels of SAM and related metabolites (S-adenosylhomocysteine and homocysteine cysteine) in 62 patients (average age, 65.9 years) with CKD (stages II-V).
RESULTS
Patients with stages III-V CKD stages have significantly decreased urine levels and SAM/S-adenosylhomocysteine ratio and also cysteine/homocysteine ratio in blood plasma (P <.05), compared with patients with stage II CKD. Urine SAM levels allowed us to distinguish patients with mildly decreased kidney function from those with moderate to severe renal impairment (AUC, 0.791; sensitivity, 85%; specificity, 78.6%).
CONCLUSIONS
Our study results demonstrate that urine SAM is a potent biomarker for monitoring renal function decline at early CKD stages. Urine SAM testing confers an additional advantage to healthcare professionals in that it is noninvasive.
目的
确定尿 S-腺苷甲硫氨酸 (SAM) 是否可作为慢性肾脏病 (CKD) 的指标。
方法
我们研究了 62 例 CKD（II-V 期）患者（平均年龄 65.9 岁）的尿 SAM 及相关代谢物（S-腺苷同型半胱氨酸和同型半胱氨酸半胱氨酸）水平。
结果
与 CKD II 期患者相比，III-V 期 CKD 患者的尿 SAM 水平和 SAM/S-腺苷同型半胱氨酸比值以及血浆中半胱氨酸/同型半胱氨酸比值显著降低（P <.05）。尿 SAM 水平可区分肾功能轻度下降和中重度肾功能损害的患者（AUC，0.791；敏感性，85%；特异性，78.6%）。
结论
我们的研究结果表明，尿 SAM 是监测早期 CKD 阶段肾功能下降的有力生物标志物。尿 SAM 检测具有非侵入性的优势，为医疗保健专业人员提供了额外的优势。
Zotero 插件